Annuncio pubblicitario
Italia markets closed
  • Dow Jones

    -52,24 (-0,14%)
  • Nasdaq

    -113,36 (-0,73%)
  • Nikkei 225

    -101,45 (-0,26%)

    +0,0002 (+0,02%)
  • Bitcoin EUR

    -465,24 (-0,98%)
  • CMC Crypto 200

    0,00 (0,00%)

    +255,59 (+1,57%)
  • S&P 500

    -12,70 (-0,26%)

Miromatrix to Ring Nasdaq Closing Bell on National Donor Day, February 14, 2022

EDEN PRAIRIE, Minn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that the Company will ring the closing bell at Nasdaq on Monday, February 14, 2022, at 4:00 p.m. ET to celebrate National Donor Day and the Company’s public listing last year on Nasdaq under the trading symbol MIRO.

Miromatrix CEO, Jeff Ross, Ph.D., will ring the closing bell alongside the Company’s team and representatives from strategic investors, including Baxter (NYSE: BAX), CareDx (NASDAQ: CDNA), and DaVita (NYSE: DVA).

“We are thrilled to celebrate such an important milestone for Miromatrix with our team, collaborators, and investors,” said Jeff Ross, Ph.D., Miromatrix CEO. “We remain steadfast in our mission of bioengineering fully transplantable human organs. Thanks to the dedication and hard work of the Miromatrix team, we have accomplished a great deal this past year, including our recent pre-IND request to the FDA for our External Liver Assist Product for the treatment of acute liver failure. We will continue to drive our objectives forward as we strive towards eliminating the organ transplant waitlist. It’s especially appropriate on National Donor Day as we honor all those who have given and received the gift of life through the national donor program.”

The ceremony will begin at approximately 3:30 p.m. ET on Monday, February 14, 2022, and can be viewed live here. A replay of the ceremony will be available at a later date on the Events & Presentations page of the Investors section of Miromatrix’s website.

About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company’s initial development focus is on human livers and kidneys. For more information, visit

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward looking statements, including statements regarding our first ever transplant of a bioengineered liver transplant into a large animal. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “outlook,” “guidance,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this press release are only predictions and are based largely on our current business plans, expectations, and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history of significant losses, which we expect to continue; our limited history operating as a commercial company; our expectations with respect to the regulatory pathway of our product candidates, our ability to obtain regulatory approvals for such product candidates, and the anticipated effect of delays in obtaining any such regulatory approvals; our expectations with respect to preclinical and clinical trial plans for our product candidates, the results of such activities and the safety and efficacy of our product candidates; our ability to commercialize our product candidates; our ability to compete successfully with larger competitors in our highly competitive industry; our ability to achieve and maintain adequate levels of coverage or reimbursement for any future products we may seek to commercialize; our ability to compete successfully with larger competitors in our highly competitive industry; our expectations regarding our manufacturing capabilities; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including the outbreak of the novel strain of coronavirus, COVID-19; product liability claims; our ability to establish and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others; our ability to attract and retain senior management and key scientific personnel; and other important factors that could cause actual results, performance or achievements to differ materially from those expected or projected. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s Registration Statement on Form S-1 (File No. 333-256649), as amended, filed with the U.S. Securities and Exchange Commission and any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Contact
Greg Chodaczek

Media Contact: